COX1 Inhibitor Screening Assay Kit
The COX1 Inhibitor Screening Assay Kit is designed to measure COX1 (cyclooxygenase 1) activity for screening and profiling applications. The assay kit comes in a convenient 96-well format, with enough purified recombinant COX1, Amplex™ Red, Arachidonic Diluent, COX Assay Buffer, and 100% ethanol for 100 enzyme reactions.
- Arachidonic Acid (Cayman Chemical #90010.1)
- Adjustable micropipettor and sterile tips
- Fluorescence plate reader capable of measurement at λex535/λem590 nm
| Catalog # | Name | Amount | Storage |
| 71110 | COX1, FLAG-His-Tags* | 70 µg | -80°C |
| Amplex™ Red | 100 µl | -80°C | |
| Arachidonic Diluent | 250 µl | -80°C | |
| COX Assay Buffer | 10 ml | -80°C | |
| 100% Ethanol | 1 ml | -80°C | |
| 79685 | 96-well black microplate | 1 | Room Temp |
* The concentration of protein is lot-specific and will be indicated on the tube containing the protein.
COX1 (cyclooxygenase 1), also known as prostaglandin-endoperoxide synthase 1 (PTGS), is a peroxidase involved in the formation of prostaglandins by converting arachidonic acid to prostaglandin H2. COX1 is expressed constitutively in most cells and participates in tissue homeostasis. COX-1 promotes cytoprotection of the gastric mucosa by increasing the formation of mucus and bicarbonate, reducing acid and pepsin secretion and keeping appropriate blood flow. It is involved in the formation of thromboxane A2 (TxA2) in platelets, which stimulates aggregation and vasoconstriction. COX1 and COX2 differ in position 523, with COX2 having a valine and COX1 an isoleucine residue, making the development of specific inhibitors a challenge. The use of COX inhibitors or NSAIDs (non-steroidal anti-inflammatory drugs) is common to manage pain and inflammation. Classical NSAIDs, such as aspirin and ibuprofen, can result in damage to the gastrointestinal system. The use of low dose aspirin can help prevent atherothrombosis and the discovery of other compounds able to inhibit COX1 may prove beneficial as coadjuvants in cardiovascular disease therapy.
Zaragoza C., et al., 2022 Molecules 27(3):1146.
Bruno A., et al., 2023 Adv Pharmacol 97:133-165.
Powered by Bioz
San Diego, CA 92121
858-202-1401
Products are for Research Use Only
COMPANY
Copyright © 2024
BPS Bioscience, Inc.
All rights reserved.
Diagrams on this website are created with BioRender.com.